Form 4 Filing for Nexalin Technology, Inc. - Owens David

David Owens, Chief Medical Officer and Director of Nexalin Technology, Inc., was granted 1,000,000 stock options on December 19, 2025. These options were granted under the 2023 Equity Incentive Plan, pending shareholder approval to increase the plan limit per NASDAQ rules. The options have an exercise price of $0.83 and an expiration date of December 19, 2030. Following this transaction, Mr. Owens holds 2,484,809 shares. The filing indicates this is a direct ownership transaction.